Celavie Biosciences

Celavet Animal Health

Celavie Biosciences Information Kit

Advancing Beyond Mainstream Stem Cell Technology

Celavie Biosciences is developing breakthrough regenerative stem cell therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS). The unmet medical needs for these conditions are significant as these diseases result in loss of basic function or mortality.

In addition to human applications, Celavie’s subsidiary, Celavet, has demonstrated restoring function in serious veterinary diseases. We are changing lives and restoring hope by changing the paradigm of stem cell technology.


Latest News

ASGCT 2020 Poster

“Human undifferentiated neural progenitor stem cells (NPC) alleviate motor dysfunction, repair morphological damage and extend life span in a spastic Han Wistar model of cerebellar ataxia” poster presented at the 2020 American Society of Cell & Gene Therapy Annual Meeting.

View Poster

Read more


ISSCR 2020 Poster

“In Vitro And In Vivo Characterization Of Clinical Grade Human Undifferentiated Neural Progenitor Stem Cells (Npc) For Treatment Of Neurodegenerative Diseases” poster presented at the 2020 International Society for Stem Cell Research Annual Meeting.

View Poster

Read more




Celavie Biosciences advancing its five year exploratory study in Parkinson’s Disease

Celavie Biosciences CEO Sandy Solomon sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York. The California-based company is developing regenerative stem cell therapies to treat Parkinson’s disease and other central nervous system disorders.

Watch Video Here

Read more


PharmaVOICE Woman of the Week Podcast with Sandy Solmon, CEO & President of Celavie

Sandy Solmon wears several hats, she leads a private, emerging medical technology company that develops stem cell-based regenerative therapies for the treatment of CNS disorders and she is CEO, chief innovator, and founder of Sweet Street Desserts, the world’s largest manufacturer of frozen gourmet desserts. From R&D to regulations, she discusses how running a global food company translates to an emerging biotech company.

Read the full article here

Read more


Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA’s Center for Veterinary Medicine and Announces Ashlee E. Watts, DVM, PhD, DACVS as Principal Investigator

OXNARD, Calif.–(BUSINESS WIRE)–Celavet Inc., a regenerative medicine company developing stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals, and a subsidiary of Celavie Biosciences, LLC, today announced Ashlee E. Watts, DVM, PhD, DACVS as principal investigator for a new equine tendinitis study being submitted to the FDA’s Center for Veterinary Medicine (CVM).

Read the full article here

Read more


Celavie Biosciences to Present at April 2020 Virtual Investor Summit

OXNARD, Calif.–(BUSINESS WIRE)–Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced that the Company will give a corporate presentation at the April 2020 Virtual Investor Summit, taking place online from April 22-23, 2020. Sandy Solmon, the Company’s President and Chief Executive Officer, will also give a corporate overview and update on recent momentum at Celavet Inc., a subsidiary of Celavie Biosciences that develops stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals. The presentation will take place on Thursday, April 23, 2020 at 1:00pm ET, followed by a live Q&A session with registered investors and other conference attendees.

Read the full article here

Read more



Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit

CEO Sandy Solmon to Present on Celavie’s Stem Cell Therapies at Upcoming Conferences in New York and Barcelona

OXNARD, CA – January 22, 2020 – Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled “Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients,” at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.

Read more


Regenerative Stem Cell Therapy Pioneer, Celavie Biosciences, LLC, to Attend Cell & Gene Meeting on the Mesa on October 2 – 4 in Carlsbad, California

OXNARD, CA – October 1, 2019 

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, announced today their attendance at the Alliance of Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Mesa to be held October 2nd – 4th in Carlsbad, California. 

Read more


Celavet Characterization of Cells Accepted by Center for Veterinary Medicine

Novel cells offer functional and structural restoration advantages for transplantation and therapy

OXNARD, Calif., February 21, 2017—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, received approval from the Center for Veterinary Medicine (CVM) for product characterization of its equine OK100 stem cells. Celavet’s donor selection criteria were approved by the CVM last August. These approvals mark significant progress towards pivotal studies for the OK100 stem cells, proposed to treat tendinitis (e.g., tendon injuries, bowed tendons, etc.) in horses.

Read more


PARKINSON’S Highlights – Recent Data

Celavie has targeted Parkinson’s disease (PD) as the first human application of its stem cells (OK99). Parkinson’s disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson’s disease. The risk of developing Parkinson’s is about 1 percent at age 60. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Read more


Celavie Biosciences Adds Strategic Business Development Team to Bring Novel Stem Cell Technology to Market

OXNARD, Calif., Sept. 22, 2016Celavie Biosciences LLC welcomed a team of leaders in market strategy, medical technology, pharmaceutical R&D, regulations, and product commercialization to help bring their novel stem cell technology to market. Celavie is working on stem cell-based regenerative therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS), for which there are no long-term treatments or cures.

Read more


Celavie Biosciences Awarded U.S. Patents for Stem Cell Technology with Applications for Central Nervous System Disorders

Novel cells offer functional and structural restoration advantages for transplantation and therapy

OXNARD, Calif., September 13, 2016—Regenerative medicine company Celavie Biosciences LLC, announced that the U.S. Patent and Trademark Office issued patents for its pluripotent stem cells with applications for a range of disorders of the central nervous system (CNS), including Parkinson’s disease.

Read more


Celavet Equine Donor Selection Criteria Accepted by Center for Veterinary Medicine

CVM approval moves novel stem cell therapy one step closer to restoring health and mobility in horses

OXNARD, Calif., Aug. 12, 2016—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, received approval from the Center for Veterinary Medicine (CVM) for the donor selection criteria of its equine OK100 stem cells. The Investigational New Animal Drug (INAD) file for the OK100 stem cells is proposed to treat tendinitis (e.g., tendon injuries, bowed tendons, etc.) in horses.

Read more


Celavie Biosciences Conducts First Clinical Trial for New Stem Cell Treatment

New stem cell technology offers potential to revolutionize regenerative medicine

OXNARD, Calif., Dec. 14, 2015—Regenerative medicine start-up Celavie Biosciences LLC has conducted its first clinical trial to evaluate the safety of their stem cells in treating eight patients suffering from Parkinson’s disease (PD). Seven of the eight patients completed first-year follow-up. No lasting adverse effects or complications over period of more than two years were observed.

Read more


Multicenter Open Label Study Investigates Treatment of Equine Tendon Injuries with Novel Stem Cells

Regenerative medicine start-up studies over 400 horses with tendon and ligament injuries

OXNARD, Calif., December 15, 2013—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, successfully completed a multicenter, open label study investigating the treatment of equine tendon and ligament injuries with Celavet’s OK100 stem cells on more than 400 horses.

Read more


Innovative Stem Cell Technology Heals Abused Pit Bull “Bernie”

Regenerative medicine start-up granted compassionate use by CVM to aid animal with severe burns

OXNARD, Calif., Aug. 31, 2011—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, provided the undifferentiated stem cells successfully used for the treatment of a pit bull with severe burns. Collaborators Dr. Boyd Wagner of Wyomissing Animal Hospital and Dr. Oleg Kopyov of Celavet administered the treatment using a new stem cell technology and a newly created protocol, which resulted in near-total restoration of damaged tissue.

Read more


Innovative Stem Cell Technology Shows Promise in Treatment of Equine Tendon Injuries

Unique pluripotent stem cells show favorable structural improvements to damaged tendons

OXNARD, Calif., March 3, 2010—A recent study from Celavet Inc., a subsidiary of Celavie Biosciences LLC, demonstrates promising indications for the efficacy of pluripotent stem cells in the treatment of tendon injuries in horses. Conducted at Cornell University’s College of Veterinary Medicine by Dr. Alan Nixon, the equine study investigates the effect of Celavet’s undifferentiated stem cells versus placebo controls in acute tendonitis lesions in horses’ superficial flexor tendons.

Read more

Contact Celavie Biosciences

Changing the Paradigm of Regenerative Medicine and Stem Cell Technology